Experience real-time quotes, in-depth charts, and analyst ratings

MARKET

TECH

Bio-Techne

NASDAQ

Real-time Quotes | Nasdaq Last Sale

361.24

-14.20

-3.78%

After Hours: 361.24 0 0.00% 16:42 03/03 EST

OPEN

372.15

PREV CLOSE

375.44

HIGH

372.32

LOW

361.10

VOLUME

162.60K

TURNOVER

52 WEEK HIGH

414.99

52 WEEK LOW

155.17

MARKET CAP

14.02B

P/E (TTM)

82.33

News

Financial

Releases

Corp Actions

Analysis

Profile

Bio-Techne to Acquire Asuragen For Initial $215 million Cash Consideration

MT Newswires · 5h ago

Global Led Temperature Regulators Market Size 2021 By Emerging Trends, Industry Share, Growth Strategy, Developing Technologies, Market Potential, Traders, Regional Overview and SWOT Analysis till 2026

The Express Wire · 17h ago

Global Hollow Blow Molding Machine Market 2020 Industry Outlook, Key Players, Segmentation Analysis, Business Growth and Forecast to 2025

Mar 02, 2021 (CDN Newswire via Comtex) -- Global Hollow Blow Molding Machine Market Growth 2020-2025 aims to fill the need of organizations of settling on...

CDN Newswire · 1d ago

RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021

NEW YORK, March 02, Mar 02, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, March 02, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX)...

GlobeNewswire · 1d ago

Bio-Techne To Present At The Barclays Global Healthcare Conference

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that , President and Chief Executive Officer, will present at the Barclays Global Healthcare Conference on at . A live webcast of the presentation can be accessed via the IR Calendar...

PR Newswire - PRF · 1d ago

Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana Covering Its ExoDx Prostate Prostate Test

MINNEAPOLIS, March 1, 2021 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Humana has awarded a contract effective April 1, 2021 to its Exosome Diagnostics laboratory,

Benzinga · 2d ago

Bio-Techne's Exosome Diagnostics Laboratory Announces Reimbursement Contract With Humana

, /PRNewswire/ -- Bio-Techne Corporation (NASDAQ:TECH) today announced that Humana has awarded a contract effective to its Exosome Diagnostics laboratory, covering the ExoDx™ Prostate (EPI) test for men. Humana is the nation's largest Medicare Advantage ...

PR Newswire - PRF · 2d ago

Global Green Tea Market Size & Share Will Reach USD 20,000 Million By 2026: Facts & Factors

Facts and Factors have published a new research report titled "Green Tea Market By Type (Iced Green Tea, Green Tea Bags, Loose-Leaf, Green Tea Instant Mixes, and Others), By Flavor (Basil, Lemon, Cinnamon, Aloe Vera, Vanilla, and Others), By Distributio...

GlobeNewswire · 5d ago

Forecast

EPSBVPSCFPS

Actual (USD)

Estimate (USD)

Income StatementMore

Net IncomeTotal RevenueOperating Income

Net Income (USD)

YoY (%)

Balance SheetMore

Total Assets (USD)

Total Liabilities (USD)

Debt to Asset (%)

Cash FlowMore

OperatingInvestingFinancing

Operating (USD)

YoY (%)

Learn about the latest financial forecast of TECH. Analyze the recent business situations of Bio-Techne through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.

Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average TECH stock price target is 411.67 with a high estimate of 465.00 and a low estimate of 365.00.

EPS

Institutional Holdings

Institutions: 617

Institutional Holdings: 39.30M

% Owned: 101.29%

Shares Outstanding: 38.80M

TypeInstitutionsShares

Increased

149

1.09M

New

101

845.49K

Decreased

142

2.16M

Sold Out

Performance
Asset Allocation
Dividend History

No Data

Industry

Biotechnology & Medical Research

-3.96%

Pharmaceuticals & Medical Research

-1.89%

Key Executives

Chairman/Independent Director

Robert Baumgartner

President/Chief Executive Officer/Director

Charles Kummeth

Chief Financial Officer/Executive Vice President - Finance

James Hippel

Corporate Executive

David Eansor

Corporate Executive

Kim Kelderman

Senior Vice President/General Counsel/Secretary

Brenda Furlow

Independent Director

Julie Bushman

Independent Director

John Higgins

Independent Director

Joseph Keegan

Independent Director

Roeland Nusse

Independent Director

Alpna Seth

Independent Director

Randolph Steer

Independent Director

Rupert Vessey

Dividends
Splits
Insider Activity

Declaration Date Dividend Per Share Ex-Div Date: 02/02/2021
Dividend USD 0.32
02/11/2021; 11/05/2020
Dividend USD 0.32
11/13/2020; 08/04/2020
Dividend USD 0.32
08/17/2020; 04/30/2020
Dividend USD 0.32
05/08/2020; 02/04/2020
Dividend USD 0.32
02/13/2020; 10/29/2019
Dividend USD 0.32
11/07/2019; 08/06/2019
Dividend USD 0.32
08/15/2019; 04/30/2019
Dividend USD 0.32
05/09/2019; 02/05/2019
Dividend USD 0.32
02/14/2019; --
Dividend USD 0.32
11/08/2018; --
Dividend USD 0.32
08/16/2018; --
Dividend USD 0.32
05/11/2018; --
Dividend USD 0.32
02/15/2018; --
Dividend USD 0.32
11/09/2017; --
Dividend USD 0.32
08/16/2017; --
Dividend USD 0.32
05/17/2017; --
Dividend USD 0.32
02/15/2017; 10/31/2016
Dividend USD 0.32
11/09/2016; 08/17/2016
Dividend USD 0.32
08/25/2016; 04/26/2016
Dividend USD 0.32
05/11/2016; --
Dividend USD 0.32
02/10/2016; --
Dividend USD 0.32
11/10/2015; 08/06/2015
Dividend USD 0.32
08/13/2015; 05/05/2015
Dividend USD 0.32
05/13/2015; 02/03/2015
Dividend USD 0.32
02/11/2015; 10/30/2014
Dividend USD 0.32
11/06/2014; 08/11/2014
Dividend USD 0.31
08/19/2014; 04/28/2014
Dividend USD 0.31
05/07/2014; 02/04/2013
Dividend USD 0.31
02/12/2014; 10/31/2013
Dividend USD 0.31
11/07/2013; 08/06/2013
Dividend USD 0.3
08/14/2013; 04/30/2013
Dividend USD 0.3
05/08/2013; 02/05/2013
Dividend USD 0.3
02/13/2013; 10/26/2012
Dividend USD 0.3
11/01/2012; 07/31/2012
Dividend USD 0.28
08/08/2012; 05/01/2012
Dividend USD 0.28
05/09/2012; 01/31/2012
Dividend USD 0.28
02/08/2012; 10/27/2011
Dividend USD 0.28
11/03/2011; 08/02/2011
Dividend USD 0.27
08/10/2011; 05/03/2011
Dividend USD 0.27
05/11/2011; 02/01/2011
Dividend USD 0.27
02/09/2011; 10/28/2010
Dividend USD 0.27
11/04/2010; --
Dividend USD 0.26
08/12/2010; 05/04/2010
Dividend USD 0.26
05/12/2010; 02/02/2010
Dividend USD 0.26
02/10/2010; 10/29/2009
Dividend USD 0.26
11/05/2009; 08/04/2009
Dividend USD 0.25
08/13/2009; 04/28/2009
Dividend USD 0.25
05/06/2009; 02/03/2009
Dividend USD 0.25
02/11/2009; 10/23/2008
Dividend USD 0.25
10/30/2008

All
Financials
Insiders

About TECH

Bio-Techne Corporation develops, manufactures and sells biotechnology reagents and instruments for the research and clinical diagnostic markets. The Company operates through two segments: Protein Sciences and Diagnostics and Genomics. The Protein Sciences reporting segment supplies specialized proteins, such as cytokines and growth factors, immunoassays, antibodies and reagents, to the biotechnology community. The Protein Sciences segment also provides an array of platforms useful in various areas of protein analysis. The Diagnostics and Genomics reporting segment provides blood chemistry and blood gas quality controls, hematology instrument controls, diagnostics immunoassays and other bulk and custom reagents for the in vitro diagnostic market.

Webull offers kinds of BIO-TECHNE Corp stock information, including NASDAQ:TECH real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TECH stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TECH stock methods without spending real money on the virtual paper trading platform.